Abstract
Compartmental models are often used to understand and predict the progression of an infectious disease such as COVID-19. The most basic of these models consider the total population of a region to be closed. Many incorporate human mobility into their transmission dynamics, usually based on static and aggregated data. However, mobility can change dramatically during a global pandemic as seen with COVID-19, making static data unsuitable. Recently, large mobility datasets derived from mobile devices have been used, along with COVID-19 infections data, to better understand the relationship between mobility and COVID-19. However, studies to date have relied on data that represent only a fraction of their target populations, and the data from mobile devices have been used for measuring mobility within the study region, without considering changes to the population as people enter and leave the region.
This work presents a unique case study in Andorra, with comprehensive datasets that include telecoms data covering 100% of mobile subscribers in the country, and results from a serology testing program that more than 90% of the population voluntarily participated in. We use the telecoms data to both measure mobility within the country and to provide a real-time census of people entering, leaving and remaining in the country. We develop multiple SEIR (compartmental) models parameterized on these metrics and show how dynamic population metrics can improve the models. We find that total daily trips did not have predictive value in the SEIR models while country entrances did. As a secondary contribution of this work, we show how Andorra’s serology testing program was likely impacted by people leaving the country. Overall, this case study suggests how using mobile phone data to measure dynamic population changes could improve studies that rely on more commonly used mobility metrics and the overall understanding of a pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Andorra Recerca + Innovacio provided financial support to the City Science Group at MIT Media Lab. The authors Alex Berke, Ronan Doorley, Luis Alonso, Kent Larson are affiliated with the City Science Group. The other authors are affiliated with Andorra Recerca + Innovacio.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the Servei Andorra Atencio Sanitaria (register number 0720) gave ethical approval for the serology study used in this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Changes were made after peer review via the PLOS ONE journal. References were added to include newer works. Our use of the reproduction number and details about our SEIR framework were further clarified. Small formatting changes were made to be in compliance with the PLOS ONE guidelines and grammatical changes were made as well. Fig5 was updated. Discussion and limitations were further expanded upon in the Results and Discussion sections.
Data Availability
This work uses 3 main data sources: (i) public COVID-19 case reports, (ii) Andorra Telecom data, (iii) results from Andorra's serology testing program. The data sources (ii) and (iii) were provided with individual level information, which are sensitive and kept private. This work uses aggregate metrics derived from these sources. Data for (i) and aggregated metrics are made available and documented in a public repository. https://github.com/CityScope/CSL_Andorra_COVID_Public The repository also includes analysis notebooks as well as the preprocessing scripts that produced the aggregated metrics.